Epics Therapeutics SA has described N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, infections, and neurological and inflammatory disorders.
Researchers from Allianthera Boston Inc. and Allianthera (Suzhou) Biopharmaceutical Co. Ltd. have prepared and tested serine/arginine-rich protein-specific kinase 1 (SRSF protein kinase 1; SRPK1) inhibitors reported to be useful for the treatment of cancer, inflammation, diabetes, age-related macular degeneration, obesity, arthritis, psoriasis and idiopathic pulmonary fibrosis.
In what represents the first patenting to emerge from Endeavor Med Inc., its founder and chief executive officer, Imran Faruqi, describes their development of a novel device capable of providing non-invasive cardiac pacing, defibrillation, and cardioversion, and which uses pacing currents at less than half that required by traditional chest pads.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Researchers from Sun Pharmaceutical Advanced Research Co. Ltd. and the University of California have synthesized drug conjugates consisting of PSMA targeting moiety covalently linked to therapeutic and/or cytotoxic agent reported to be useful for the treatment of cancer.
Mitsubishi Tanabe Pharma Corp. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase (CRBN) binding moiety coupled to disease-associated protein targeting moiety through a linker reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune disease, neurodegeneration and genetic disorders.
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity, among others.
Angel Pharmaceuticals Co. Ltd. has prepared and tested protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yiweikang Pharmaceutical Co. Ltd. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, inflammatory and immunological disorders.
RSS
